Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.
OBJECTIVE
We assessed the ability of diagnostic tests to distinguish clinically unimportant cancers.


METHODS
We correlated T stage (based on digital examination and ultrasound), prostate specific antigen (PSA), PSA density and pathological features of cancer in systematic biopsy specimens with features of cancer in 170 radical prostatectomy specimens. Clinically unimportant cancers were defined as small (0.5 cm.3 or less), well or moderately differentiated and confined to the prostate.


RESULTS
Of the patients 10% had an unimportant cancer. On logistic regression analysis the 2 significant predictors were maximum length of cancer in any core and PSA density. Of 12 patients with maximum cancer length 2 mm. or less and PSA density less than 0.1., 75% had an unimportant cancer compared to 5% of the remaining 158 (p < 0.0005).


CONCLUSIONS
Quantitative analysis of systematic biopsy specimens combined with PSA density provides valuable staging information and helps to identify cancers of low biological potential.
Goto
Y
Y
Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
Ohori
M
M
Arakawa
A
A
Kattan
M W
MW
Wheeler
T M
TM
Scardino
P T
PT
D000368:Aged; D001707:Biopsy, Needle / Q000379:methods*; D003937:Diagnosis, Differential; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology*; D014463:Ultrasonography
D017430:Prostate-Specific Antigen